Showing results (1221-1230 of 2,691) with videos related to

Sort By:
Pageof 270
The Lancet. Infectious Diseases|August 21, 2025
A clinical practice guideline for tuberculous meningitisJoseph Donovan, Fiona V Cresswell, Elizabeth W Tucker, et al.
The Lancet. Infectious Diseases|March 3, 2023
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statementJosé Domínguez, Martin J Boeree, Emmanuelle Cambau, et al.
The Lancet. Infectious Diseases|November 10, 2022
Efficacy and safety of moxidectin and albendazole compared with ivermectin and albendazole coadministration in adolescents infected with Trichuris trichiura in Tanzania: an open-label, non-inferiority, randomised, controlled, phase 2/3 trialSophie Welsche, Emmanuel C Mrimi, Jan Hattendorf, et al.
The Lancet. Infectious Diseases|August 11, 2022
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscapeNatalie I Mazur, Jonne Terstappen, Ranju Baral, et al.
The Lancet. Infectious Diseases|August 30, 2021
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort studyKatherine A Twohig, Tommy Nyberg, Asad Zaidi, et al.
The Lancet. Infectious Diseases|March 9, 2023
Efficacy, safety, and palatability of arpraziquantel (L-praziquantel) orodispersible tablets in children aged 3 months to 6 years infected with Schistosoma in Côte d'Ivoire and Kenya: an open-label, partly randomised, phase 3 trialEliézer K N'Goran, Maurice R Odiere, Ronald Assandé Aka, et al.
The Lancet. Infectious Diseases|November 17, 2022
Effect of systematic tuberculosis detection on mortality in young children with severe pneumonia in countries with high incidence of tuberculosis: a stepped-wedge cluster-randomised trialOlivier Marcy, Eric Wobudeya, Hélène Font, et al.
The Lancet. Infectious Diseases|November 18, 2022
Déjà vu all over again? Monkeypox and the urgent need for randomised controlled trialsDavid A Lindholm, Andre C Kalil
The Lancet. Infectious Diseases|March 1, 2025
Development of the Mycetoma Activity and Severity clinical Scale (MASS): an international Delphi studyDavid J Chandler, Gail Davey, Roderick J Hay, et al.
The Lancet. Infectious Diseases|February 27, 2025
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trialGhady Haidar, Steven Thomas, Paul Loubet, et al.
Pageof 270